COPENHAGEN (Reuters) - Novo Nordisk <NOVOb.CO said on Thursday it could launch its new long-acting insulin Tresiba, a crucial future growth driver for the Danish company, at the start of 2016 in the United States.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment